Streetbeat News

Price Targets

CADL

HC Wainwright & Co. analyst Vernon Bernardino reiterated a Buy rating on Candel Therapeutics (NASDAQ:CADL) and maintained an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:16 am

KRYS

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $119 to $139.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:14 am

LEGN

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained a $77 price target.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:13 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Genmab (NASDAQ:GMAB) and raises the price target from $47 to $51.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:12 am

GMDA

HC Wainwright & Co. analyst Vernon Bernardino reiterated a Buy rating on Gamida Cell (NASDAQ:GMDA) and maintained an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:11 am

BEEM

HC Wainwright & Co. analyst Amit Dayal reiterates a Buy rating on Beam Global (NASDAQ:BEEM) and maintains a $30 price target.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:10 am

DARE

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Dare Bioscience (NASDAQ:DARE) and maintained a $7 price target.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:08 am

CYTK

HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintains a $49 price target.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:08 am

WMT

Barclays analyst Seth Sigman maintains an Overweight rating on Walmart (NYSE:WMT) and raises the price target from $159 to $162.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:07 am

NVDA

Nvidia is set to report Q1 results with an expected EPS of $0.92 and revenue of $6.52 billion. KeyBanc analyst John Vinh maintains an Overweight rating on Nvidia shares and raises the price target from $320 to $375, citing the company's strong position in generative AI and multiple new product cycles.

Portfolio Pulse from Shanthi Rexaline

May 22, 2023 | 10:06 am